Hemogenyx Pharmaceuticals PLC Directorate Change (5017W)

TIDMHEMO

RNS Number : 5017W

Hemogenyx Pharmaceuticals PLC

15 November 2017

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Directorate change

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that following the successful completion of the Company's readmission and trading on the main market of the London Stock Exchange, Timothy Le Druillenec, Finance Director, has advised the Board of his intention to step down as a Director at the end of the month and will not be seeking re-election at the forthcoming annual general meeting of the Company in order to pursue other interests.

Timothy was previously Chief Financial Officer of Silver Falcon plc and the Board is in process of putting in place appropriate arrangements for the future financial management of the Company.

Dr Robin Campbell, Chairman of Hemogenyx, commented: "I would like to thank Timothy for his contribution to the Company, and in particular his support during the successful acquisition of Hemogenyx and our listing on the London Stock Exchange."

Enquiries:

 
 Hemogenyx Pharmaceuticals Limited                                        www.hemogenyx.com 
 Dr Vladislav Sandler, Chief                                                Via Walbrook PR 
  Executive Officer & Co-Founder 
 Dr Robin Campbell, Chairman 
 
 Optiva Securities Ltd                                             Tel: +44 (0)20 3137 1902 
 Christian Dennis 
 
 Shard Capital Partners LLP                                        Tel: +44 (0)20 7186 9950 
 Damon Heath, Erik Woolgar 
 
 Peterhouse Corporate Finance                                      Tel: +44 (0)20 7469 0930 
  Limited 
 Lucy Williams/Duncan Vasey 
 
 Walbrook PR                           Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com 
 Paul McManus                                                      Mob: +44 (0)7980 541 893

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAGGGBUGUPMGMC

(END) Dow Jones Newswires

November 15, 2017 02:01 ET (07:01 GMT)

Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Mar 2024 to Apr 2024